What if we could selectively starve cancers of the amino acids they need to grow?
What if a cancer cell’s nutritional needs were different than healthy cells?
Faeth Therapeutics is beginning three clinical trials to explore the bold idea that precision nutrition could improve patient outcomes as an adjunct to mainstream therapies.
Future Ventures is proud to have co-led their first round of funding with KV, announced today:
• Business Wire overview
• TechCrunch interview
• Learn more or join a clinical trial: Faeth site
Leave a Reply